Ivabradine Tablet
Product Images NDC 70710-1472

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 70710-1472). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Cbea8583 E207 402a B79a 83ff14a3fa9b 01)

Chemical structure of ivabradine hydrochloride, showing its molecular arrangement including methoxy groups and a bridged bicyclic system.*

FDA Label Image

Image (Cbea8583 E207 402a B79a 83ff14a3fa9b 02)

A forest plot chart depicting the pharmacokinetic changes of ivabradine when coadministered with various substances. The x-axis shows fold change relative to ivabradine alone. The interventions include strong and moderate CYP3A4 inhibitors, CYP3A4 inducers, and other drugs, with their effects on Cmax and AUC presented alongside dosing recommendations such as contraindicated or avoid use.*

FDA Label Image

Image (Cbea8583 E207 402a B79a 83ff14a3fa9b 03)

A line graph displaying the proportion of subjects with heart failure hospitalization or cardiovascular death (%) over 36 months. Two curves compare Ivabradine and placebo groups, showing the Ivabradine group has a consistently lower proportion. Below the graph, a table shows the number of subjects at risk at various time points for both groups.*

FDA Label Image

Image (Cbea8583 E207 402a B79a 83ff14a3fa9b 04)

A forest plot showing hazard ratios (HR) with 95% confidence intervals comparing ivabradine versus placebo across various subgroups. Subgroups include age, sex, race, cause of heart failure, weight quartile, baseline heart rate quartile, NYHA class, baseline left ventricular ejection fraction quartile, baseline beta blocker use quartile, baseline aldosterone antagonist use, diabetes status, and hypertension status. The overall HR favors ivabradine versus placebo.*

FDA Label Image

5 mg (Cbea8583 E207 402a B79a 83ff14a3fa9b 05)

Ivabradine Tablets 5 mg film-coated tablets label from Zydus Pharmaceuticals USA Inc. The label shows the product name, strength of 5 mg, package count of 60 tablets, and includes storage instructions and dosage guidance reference. It is marked for prescription use only and features the Zydus logo with relevant barcodes and manufacturing details.*

FDA Label Image

7.5 mg (Cbea8583 E207 402a B79a 83ff14a3fa9b 06)

Label for Ivabradine Tablets 7.5 mg, oral film-coated tablets produced by Zydus Pharmaceuticals USA Inc. The label includes dosage strength, quantity of 60 tablets per bottle, storage instructions, and directions for pharmacists dispensing the medication guide separately to patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.